Outcomes | Treatment strategy | ||||||
1 | 2 | 3 | 4 | 5 | 6 | ||
Costs | Hospital LOS (days) | 1 588 763 | 1 606 829 | 1 578 887 | 1 552 681 | 1 546 424 | 1 539 156 |
Hospitalisation costs (¥) (US$)* | 3 898 198 802 559 781 348* | 3 934 038 268 564 927 895* | 3 865 333 768 555 061 929* | 3 800 624 287 545 769 648* | 3 785 797 947 543 640 585* | 3 768 864 687 541 208 969* | |
Health outcomes | LYs lost (years) | 183 175 | 95 630 | 89 558 | 83 612 | 82 976 | 82 448 |
QALYs lost | 142 999 | 74 715 | 69 977 | 65 337 | 64 840 | 64 428 | |
Incremental outcomes | INMB (¥) (US$)* | / | 21 341 431 540 3 064 629 569* | 22 893 657 435 3 287 529 208* | 24 410 857 816 3 505 399 182* | 24 581 156 000 3 529 854 002* | 24 727 102 215 3 550 811 878* |
1—current treatment strategy; 2—CAZ-AVI at the third line; 3—CAZ-AVI at the second line; 4—CAZ-AVI at the first line; 5—CAZ/AVI first line, two lines diversified; 6—CAZ/AVI first line, all-lines diversified.
The incremental net monetary benefit describes the maximum cost at the defined willingness-to-pay threshold for the additional benefit of alternative treatment strategies.
INMB = QALYS gained × willingness-to-pay per QALY − incremental costs
*Exchange rate: ¥1=US$0.1436 (9 December 2022).
INMB, incremental net monetary benefit; LOS, length of stay; LYs, life years; QALYs, quality-adjusted life years.